IDEAYA Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- IDEAYA Biosciences's estimated annual revenue is currently $35.5M per year.
- IDEAYA Biosciences received $94.0M in venture funding in March 2018.
- IDEAYA Biosciences's estimated revenue per employee is $277,734
- IDEAYA Biosciences's total funding is $226.1M.
- IDEAYA Biosciences's current valuation is $686M. (January 2022)
Employee Data
- IDEAYA Biosciences has 128 Employees.
- IDEAYA Biosciences grew their employee count by 16% last year.
IDEAYA Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Finance | Reveal Email/Phone |
2 | VP, Clinical Operations | Reveal Email/Phone |
3 | VP, Head CMC | Reveal Email/Phone |
4 | VP, Head Computational Biology | Reveal Email/Phone |
5 | Head Clinical Operations | Reveal Email/Phone |
6 | VP and Head Medicinal Chemistry | Reveal Email/Phone |
7 | VP Early Oncology Clinical Development | Reveal Email/Phone |
8 | Senior Director | Reveal Email/Phone |
9 | Director, Corporate Strategy and Business Development | Reveal Email/Phone |
10 | Senior Director | Reveal Email/Phone |
IDEAYA Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is IDEAYA Biosciences?
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA's investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$226.1M
Total Funding
128
Number of Employees
$35.5M
Revenue (est)
16%
Employee Growth %
$686M
Valuation
N/A
Accelerator
IDEAYA Biosciences News
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted...
Get IDEAYA Biosciences alerts: 83.7% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 23.5% of Pasithea...
Mackey brings over 30 years of life sciences research, development and operational experience to IDEAYA. As Senior Vice President of Pfizer...
SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commission ...
SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions. ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.1M | 130 | 7% | N/A |
#2 | $26.9M | 131 | 10% | N/A |
#3 | $35.4M | 131 | 28% | $239.8M |
#4 | $21.2M | 137 | -26% | $110M |
#5 | $41.8M | 137 | -1% | N/A |
IDEAYA Biosciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-05-04 | $46.0M | A | Multiple | Article |
| 2018-03-16 | $94.0M | B | Multiple | Article |